Group
Anti-PD-(L)1 mAb
The data below refer to patients treated with Anti-PD-(L)1 mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Combination therapy data are available in the section below.
Location
Treated site
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.
Atezolizumab
Avelumab
Camrelizumab
Durvalumab
Nivolumab
Pembrolizumab
Sintilimab
Tislelizumab
Toripalimab
Cemiplimab
No data
Cosibelimab
No data
Dostarlimab
No data
Penpulimab
No data
Retifanlimab
No data
Serplulimab
No data
Sugemalimab
No data